Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing reports an increase in notional interests in Ordinary shares for a connected person. This change resulted from the notional re-investment of a dividend paid to shareholders on January 5, 2012, at a price of 1482 pence per Ordinary share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, or outlook. It notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant three-year measurement period. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: January 10, 2012.
- Individuals Involved: Mr P C Thomson (Director/PDMR) and Mrs K Thomson (Connected Person).
- Transaction Details: Increase of 24,715 Ordinary shares via notional dividend re-investment.
- Share Price: 1482 pence per Ordinary share.
- Dividend Reference: Based on the dividend paid on January 5, 2012.